JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
Addiction
PUBLISHED: 09-25-2014
Show Abstract
Hide Abstract
To evaluate the cost-effectiveness of rapid hepatitis C virus (HCV) and simultaneous HCV/HIV antibody testing in substance abuse treatment programs.
Related JoVE Video
Current Practices of Screening for Incident Hepatitis C Virus (HCV) Infection Among HIV-Infected, HCV-Uninfected Individuals in Primary Care.
Clin. Infect. Dis.
PUBLISHED: 09-03-2014
Show Abstract
Hide Abstract
?Human immunodeficiency virus (HIV)-infected, hepatitis C virus (HCV)-uninfected patients are at risk for incident HCV infection, but little is known about screening practices for incident HCV among HIV-infected individuals in HIV primary care clinics.
Related JoVE Video
Quality of hepatitis C care at an urban tertiary care medical center.
J Health Care Poor Underserved
PUBLISHED: 05-27-2014
Show Abstract
Hide Abstract
More effective treatment for hepatitis C virus (HCV) creates an opportunity to improve health outcomes.
Related JoVE Video
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
AIDS
PUBLISHED: 03-28-2014
Show Abstract
Hide Abstract
To evaluate the effectiveness and cost-effectiveness of strategies to treat hepatitis C virus (HCV) in HIV/HCV coinfected patients in the United States.
Related JoVE Video
The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic.
AIDS Patient Care STDS
PUBLISHED: 01-17-2014
Show Abstract
Hide Abstract
United States guidelines endorse one-time HCV antibody screening at HIV diagnosis. Rescreening HCV-seronegative patients on a regular basis is still not policy, although HIV-infected persons have reasonably substantial HCV incidence. We evaluated routine risk factor-independent HCV antibody re-testing in a Rhode Island HIV clinic. We instituted annual HCV antibody testing for HCV-seronegative patients who had not been rescreened in a year or more. Testing based on clinical suspicion continued. We conducted a chart review of new antibody-positive cases in the first year of rescreening, July 2006 to June 2007. Of 245 rescreened patients, 11 (4.5%) seroconverted. Five (45%) were female. Median time between last negative and first positive result was 32 months (range 8-98 months). Six (55%) had documented risk factors and 6 (55%) elevated ALT (> 45 ?IU/L) between antibody tests; none prompted re-testing. One seroconverter died of hepatocellular carcinoma 3.7 years after HCV diagnosis. A twelfth was rescreened for suspected acute HCV based on ALT of 515 ?IU/L. He had newly detectable HCV RNA then seroconversion, and achieved SVR following 6 months of treatment in the acute phase for genotype 1 infection. Incident HCV is not uncommon among HIV-infected patients in care. Rescreening identified undiagnosed HCV in this population. HCV RNA should be checked promptly in HCV-seronegative persons with ALT elevation. We observed consequences of late diagnosis (hepatocellular carcinoma) and benefits of early diagnosis (cure with treatment of acute HCV). Adding annual rescreening to the Ryan White Program would facilitate earlier identification of undiagnosed HCV and create an instant widespread surveillance system, providing HCV incidence data.
Related JoVE Video
Hepatitis C screening trends in a large integrated health system.
Am. J. Med.
PUBLISHED: 01-14-2014
Show Abstract
Hide Abstract
As new hepatitis C virus (HCV) therapies emerge, only 1%-12% of individuals are screened in the US for HCV infection. Presently, HCV screening trends are unknown.
Related JoVE Video
The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.
PLoS ONE
PUBLISHED: 01-01-2014
Show Abstract
Hide Abstract
As highly effective hepatitis C virus (HCV) therapies emerge, data are needed to inform the development of interventions to improve HCV treatment rates. We used simulation modeling to estimate the impact of loss to follow-up on HCV treatment outcomes and to identify intervention strategies likely to provide good value for the resources invested in them.
Related JoVE Video
Impact of new therapeutics for hepatitis C virus infection in incarcerated populations.
Top Antivir Med
PUBLISHED: 04-19-2013
Show Abstract
Hide Abstract
Inmate populations bear a disproportionate share of the burden of hepatitis C virus (HCV) infection. With more than 90% of prisoners released back to their communities within a few years of sentencing, incarceration can be viewed as an opportunity to provide HCV screening and therapeutic interventions to benefit the individual, reduce the costs of HCV management to the health care system from a societal perspective, and improve overall public health. Although optimal medical management of HCV within prison settings would increase the current cost of correctional health care, it could decrease transmission within the community, reduce overall disease burden, and lower the future societal health care costs associated with end-stage liver disease. Nonetheless, most prison systems treat only a small fraction of infected inmates. Current and emerging therapeutic agents will cure HCV infection in the vast majority of patients. Mathematical modeling also shows that expanded HCV screening and treatment are cost-effective from the societal perspective. In this article, we will describe appropriate treatment regimens, propose strategies to lessen the burden of these costly HCV therapies on correctional health care systems, and address the challenges of expanded HCV screening in correctional settings.
Related JoVE Video
Cost-effectiveness of surveillance strategies after treatment for high-grade anal dysplasia in high-risk patients.
Sex Transm Dis
PUBLISHED: 03-15-2013
Show Abstract
Hide Abstract
Anal cancer is one of the most common cancers affecting human immunodeficiency virus (HIV)-infected male patients. Currently, there is no consensus on posttreatment surveillance of HIV-infected men who have sex with men (MSM) who have been treated for high-grade intraepithelial neoplasia (HGAIN), the likely precursor to anal cancer.
Related JoVE Video
Priorities for screening and treatment of latent tuberculosis infection in the United States.
Am. J. Respir. Crit. Care Med.
PUBLISHED: 05-13-2011
Show Abstract
Hide Abstract
To improve the effectiveness of tuberculosis (TB) control programs in the United States by identifying cost-effective priorities for screening for latent tuberculosis infection (LTBI).
Related JoVE Video
Improving outcomes in state AIDS drug assistance programs.
J. Acquir. Immune Defic. Syndr.
PUBLISHED: 06-30-2009
Show Abstract
Hide Abstract
State AIDS Drug Assistance Programs (ADAPs) provide antiretroviral medications to patients with no access to medications. Resource constraints limit the ability of many ADAPs to meet demand for services.
Related JoVE Video
Written informed-consent statutes and HIV testing.
Am J Prev Med
PUBLISHED: 03-10-2009
Show Abstract
Hide Abstract
Almost 1 million Americans are infected with HIV, yet it is estimated that as many as 250,000 of them do not know their serostatus. This study examined whether people residing in states with statutes requiring written informed consent prior to HIV testing were less likely to report a recent HIV test.
Related JoVE Video
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
Clin. Infect. Dis.
Show Abstract
Hide Abstract
We used a Monte Carlo computer simulation to estimate the effectiveness and cost-effectiveness of screening for acute hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected men who have sex with men.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.